Drug Profile
AZD 9742
Alternative Names: AZD9742Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Methicillin-resistant Staphylococcus aureus infections
Most Recent Events
- 28 Jul 2011 Discontinued - Phase-I for Methicillin-resistant Staphylococcus aureus infections in USA (IV)
- 30 Nov 2009 Phase-I clinical trials in Methicillin-resistant Staphylococcus aureus infections in USA (IV)